Speaker Profile

Ph.D., Chief Strategy Officer and Head of Drug Discovery, BioSymetrics

Stacie is a pharmaceutical R&D and biotech leader with expertise in AI and machine learning applications for drug discovery. At BioSymetrics she guides the company on its drug discovery and partnering strategies, with a focus on translating human-relevant disease biology. Prior to BioSymetrics, Stacie led collaborations and partnerships in the AI-powered drug discovery space as Vice President and Head of AI Molecular Screening Partnerships at Atomwise. Previously she established and co-led the Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium, a public-private partnership developing machine learning tools to accelerate drug discovery. She worked at GSK for more than 13 years, starting as a process chemist and moving up into R&D strategy and operations roles where she led several change initiatives and teams. Stacie holds a B.S. in Chemistry from University of California Berkeley and a Ph.D. in chemistry from University of California Irvine.

 Session Abstract – PMWC 2022 Silicon Valley

  • Hope or Hype? The Role of ML in Drug Discovery and Development (PANEL)
    Session Chair: Ansuman Satpathy, Stanford University
    - Marcel Hop, Genentech
    - Noam Solomon, ImmunAI
    - Stacie Calad-Thomson, BioSymetrics
    - Marina Sirota, UCSF
  • Advancing Research and Drug Discovery with UK Biobank
    Session Chair: Asha Collins, DNAnexus
    - Mark Effingham, UK Biobank
  • AI in Small Molecule Design and Screening
    Session Chair: Alex Zhavoronkov, Insilico Medicine
    - Najat Khan, Johnson & Johnson
    - Martin Emanuel Bittner, Arctoris
  • AI/ML in Clinical Trial Design, Patient Selection and Prediction of Outcomes
    Session Chair: Peter Lipsky, Ampel Bio
    - Mika Newton, xCures, Inc.
    - Mark Smith, MedStar Health
    - William Oh, Sema4
  • Emerging Data-driven Clinical Trials
    Session Chair: Adrian Lee, UPMC
    - Laura Esserman, UCSF
    - Derek Angus, UPMC
  • Generating Novel Insights through AI and Multimodal Analysis
    - Philippe Menu, SOPHiA GENETICS
  • Pfize's Data and Analytics Efforts
    - Susie Stephens, Pfizer
  • PMWC 2022 Showcase
    - Kevin Cho, Envisagenics, Inc.
    - Poojitha Ojamies, Novartis